<DOC>
	<DOC>NCT00564447</DOC>
	<brief_summary>The purpose of this study is to evaluate the drug concentrations of AzaSiteâ„¢ compared to Vigamox at various time points in conjunctiva tissue of healthy volunteers</brief_summary>
	<brief_title>Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Eye Infections</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Have best corrected visual acuity of 0.60 logMAR or better in each eye as measured using Early Treatment of Diabetic Retinopathy Study chart Have a known allergy and/or sensitivity to the test article(s) or its components or any therapies associated with the trial Have active signs or symptoms of any clinically significant ocular disorder (other than refractive disorders) Have a known bleeding disorder or history of bleeding complications after surgical or dental procedures Take aspirin, or take any other blood thinners or anticoagulants (e.g. warfarin) including prescription, over the counter, or homeopathic therapies Have undergone any ocular surgical intervention within 3 months prior to Visit 1 or anticipate having ocular surgery during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>